Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Voyager Therapeutics stock
Learn how to easily invest in Voyager Therapeutics stock.
Voyager Therapeutics Inc is a biotechnology business based in the US. Voyager Therapeutics shares (VYGR) are listed on the NASDAQ and all prices are listed in US Dollars. Voyager Therapeutics employs 177 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Voyager Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VYGR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Voyager Therapeutics stock price (NASDAQ: VYGR)Use our graph to track the performance of VYGR stocks over time.
Voyager Therapeutics shares at a glance
|Latest market close||$2.94|
|52-week range||$2.46 - $9.15|
|50-day moving average||$3.12|
|200-day moving average||$3.72|
|Wall St. target price||$6.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.47|
Buy Voyager Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Voyager Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Voyager Therapeutics price performance over time
|1 week (2022-01-12)||2.08%|
|1 month (2021-12-17)||-1.67%|
|3 months (2021-10-15)||N/A|
|6 months (2021-07-19)||-12.24%|
|1 year (2021-01-19)||-66.09%|
|2 years (2020-01-17)||-78.68%|
|3 years (2019-01-18)||8.26|
|5 years (2017-01-18)||11.58|
Is Voyager Therapeutics stock undervalued or overvalued?
Valuing Voyager Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Voyager Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Voyager Therapeutics's EBITDA
Voyager Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.1 million.
The EBITDA is a measure of a Voyager Therapeutics's overall financial performance and is widely used to measure a its profitability.
Voyager Therapeutics financials
|Revenue TTM||$15.9 million|
|Gross profit TTM||$62.4 million|
|Return on assets TTM||-27.79%|
|Return on equity TTM||-73.2%|
|Market capitalisation||$107.8 million|
TTM: trailing 12 months
Voyager Therapeutics share dividends
We're not expecting Voyager Therapeutics to pay a dividend over the next 12 months.
Voyager Therapeutics share price volatility
Over the last 12 months, Voyager Therapeutics's shares have ranged in value from as little as $2.46 up to $9.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Voyager Therapeutics's is 1.1901. This would suggest that Voyager Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Voyager Therapeutics overview
Voyager Therapeutics, Inc. , a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc. , as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc.
Voyager Therapeutics in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Voyager Therapeutics is owned by insiders or institutions?
Currently 13.98% of Voyager Therapeutics shares are held by insiders and 65.098% by institutions. How many people work for Voyager Therapeutics?
Latest data suggests 177 work at Voyager Therapeutics. When does the fiscal year end for Voyager Therapeutics?
Voyager Therapeutics's fiscal year ends in December. Where is Voyager Therapeutics based?
Voyager Therapeutics's address is: 75 Sidney Street, Cambridge, MA, United States, 02139 What is Voyager Therapeutics's ISIN number?
Voyager Therapeutics's international securities identification number is: US92915B1061 What is Voyager Therapeutics's CUSIP number?
Voyager Therapeutics's Committee on Uniform Securities Identification Procedures number is: 92915B102
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert